JP4614661B2 - 生体活性因子を含有する処方物およびそれを使用する方法 - Google Patents

生体活性因子を含有する処方物およびそれを使用する方法 Download PDF

Info

Publication number
JP4614661B2
JP4614661B2 JP2003565426A JP2003565426A JP4614661B2 JP 4614661 B2 JP4614661 B2 JP 4614661B2 JP 2003565426 A JP2003565426 A JP 2003565426A JP 2003565426 A JP2003565426 A JP 2003565426A JP 4614661 B2 JP4614661 B2 JP 4614661B2
Authority
JP
Japan
Prior art keywords
bmp
solution
microparticle
microparticles
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003565426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524421A (ja
JP2005524421A5 (https=
Inventor
スーザン ジェイ． ソフィア，
ダニエル シュヴァルツ，
ヴォルフガング フリース，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2005524421A publication Critical patent/JP2005524421A/ja
Publication of JP2005524421A5 publication Critical patent/JP2005524421A5/ja
Application granted granted Critical
Publication of JP4614661B2 publication Critical patent/JP4614661B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2003565426A 2002-02-08 2003-02-10 生体活性因子を含有する処方物およびそれを使用する方法 Expired - Fee Related JP4614661B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35513502P 2002-02-08 2002-02-08
PCT/US2003/003809 WO2003066000A2 (en) 2002-02-08 2003-02-10 Formulation comprising bioactive agents and method of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009284564A Division JP2010059211A (ja) 2002-02-08 2009-12-15 生体活性因子を含有する処方物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2005524421A JP2005524421A (ja) 2005-08-18
JP2005524421A5 JP2005524421A5 (https=) 2006-03-16
JP4614661B2 true JP4614661B2 (ja) 2011-01-19

Family

ID=27734467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003565426A Expired - Fee Related JP4614661B2 (ja) 2002-02-08 2003-02-10 生体活性因子を含有する処方物およびそれを使用する方法
JP2009284564A Pending JP2010059211A (ja) 2002-02-08 2009-12-15 生体活性因子を含有する処方物およびそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009284564A Pending JP2010059211A (ja) 2002-02-08 2009-12-15 生体活性因子を含有する処方物およびそれを使用する方法

Country Status (6)

Country Link
US (2) US7897174B2 (https=)
EP (1) EP1578348A4 (https=)
JP (2) JP4614661B2 (https=)
AU (2) AU2003209071B2 (https=)
CA (1) CA2474919A1 (https=)
WO (1) WO2003066000A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4614661B2 (ja) * 2002-02-08 2011-01-19 ワイス 生体活性因子を含有する処方物およびそれを使用する方法
US7454785B2 (en) * 2002-12-19 2008-11-18 Avocent Huntsville Corporation Proxy method and system for secure wireless administration of managed entities
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
DE202017101042U1 (de) 2017-02-24 2017-03-24 Manitowoc Crane Group France Sas Verbolzungseinheit
US10675330B2 (en) 2018-03-21 2020-06-09 Warsaw Orthopedic, Inc. Injectable bone morphogenetic protein

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6559119B1 (en) * 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
WO1993000050A1 (en) * 1991-06-21 1993-01-07 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
ATE238417T1 (de) * 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
WO1996039169A1 (en) * 1995-06-05 1996-12-12 Genetics Institute, Inc. Methods and compositions for healing and repair of connective tissue attachment
US5674292A (en) * 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
CA2223583A1 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics Inc. Device for releasing aggregation-stabilized, biologically active agent
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
ZA9711580B (en) * 1996-12-25 1999-09-23 Hoechst Marion Roussel Ltd Process for the production of purified dimeric bone morphogenetic factors.
CA2334075A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Bone morphogenic protein
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6696410B1 (en) * 1999-09-27 2004-02-24 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
WO2001070288A2 (en) * 2000-03-23 2001-09-27 Genetics Institute, Inc. Thermoreversible polymers for delivery and retention of osteoinductive proteins
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
JP4614661B2 (ja) * 2002-02-08 2011-01-19 ワイス 生体活性因子を含有する処方物およびそれを使用する方法
US7270813B2 (en) * 2002-10-08 2007-09-18 Osteotech, Inc. Coupling agents for orthopedic biomaterials
EP1462126A1 (en) * 2003-03-28 2004-09-29 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Improved Osteoinductive Materials
US7671012B2 (en) * 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US8372419B2 (en) * 2004-03-10 2013-02-12 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
ATE520711T1 (de) * 2005-05-27 2011-09-15 Bbs Bioactive Bone Substitutes Oy Knochenmorphogenetisches protein 4 und osteogene vorrichtungen und pharmazeutische produkte, die dieses enthalten
CA2627907C (en) * 2005-11-01 2014-06-17 Osteotech, Inc. Osteoinductive composition comprising osteoinductive factors recovered from mineralized bone and a carrier
CA2690457C (en) * 2007-06-15 2018-02-20 Osteotech, Inc. Bone matrix compositions and methods
US8524253B2 (en) * 2008-11-25 2013-09-03 Warsaw Orthopedic, Inc. Bone regeneration device

Also Published As

Publication number Publication date
EP1578348A4 (en) 2011-03-16
EP1578348A3 (en) 2005-12-21
US20120004170A1 (en) 2012-01-05
US20030223983A1 (en) 2003-12-04
AU2003209071A1 (en) 2003-09-02
WO2003066000A3 (en) 2005-11-03
US7897174B2 (en) 2011-03-01
WO2003066000A2 (en) 2003-08-14
JP2010059211A (ja) 2010-03-18
AU2008243150B2 (en) 2011-02-17
JP2005524421A (ja) 2005-08-18
CA2474919A1 (en) 2003-08-14
EP1578348A2 (en) 2005-09-28
AU2008243150A1 (en) 2008-12-04
AU2003209071B2 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
JP2010059211A (ja) 生体活性因子を含有する処方物およびそれを使用する方法
AU669133B2 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
AU695374B2 (en) Formulations for delivery of osteogenic proteins
EP0535091B1 (en) Osteoinductive pharmaceutical formulations
KR100329409B1 (ko) 인간 골 형태발생 단백질을 사용한 신경 재생법
JP3351525B2 (ja) 骨形成性蛋白医薬処方物
ES2233469T3 (es) Formulaciones para la administracion de proteinas osteogenicas.
EP2523672B1 (en) Use of vanadium compounds to accelerate bone healing
JP2003512341A (ja) 骨形成蛋白をデリバリーするためのヒアルロン酸の処方
JP2002531489A (ja) 中枢神経系への神経栄養剤の投与
JP2019510010A (ja) 長期間の安定性を有する脱細胞化ヒト羊水調製物
KR20110127746A (ko) 주사용 바이오물질
JP2002539172A (ja) Ｔｇｆ−ベータを含む医薬組成物
US8029769B2 (en) Protein formulation
JPH03163032A (ja) 脳内投与用徐放性製剤
CN102068688A (zh) 力生长因子及其e肽在制备治疗骨质疏松或骨缺损的药物及材料中的应用
EP1830863A2 (en) Protein formulation
WO2007046540A1 (ja) 象牙質－歯髄複合体再生治療剤
WO2010008023A1 (ja) 骨延長促進剤
EP1862170A1 (en) Protein formulation
HK1178799B (en) Use of vanadium compounds to accelerate bone healing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100420

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101007

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101019

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131029

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees